MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 57 filers reported holding MEREO BIOPHARMA GROUP PLC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,500,125 | -2.3% | 7,364,438 | 0.0% | 0.51% | -1.3% |
| Q2 2023 | $9,721,058 | +86.7% | 7,364,438 | 0.0% | 0.52% | +136.4% |
| Q1 2023 | $5,205,921 | -5.7% | 7,364,438 | 0.0% | 0.22% | -5.2% |
| Q4 2022 | $5,523,329 | -12.9% | 7,364,438 | 0.0% | 0.23% | -11.8% |
| Q3 2022 | $6,342,000 | -38.1% | 7,364,438 | -19.4% | 0.26% | -32.4% |
| Q2 2022 | $10,239,000 | 0.0% | 9,142,067 | 0.0% | 0.39% | +24.3% |
| Q1 2022 | $10,239,000 | -30.0% | 9,142,067 | 0.0% | 0.31% | +10.6% |
| Q4 2021 | $14,627,000 | -33.9% | 9,142,067 | 0.0% | 0.28% | -24.1% |
| Q3 2021 | $22,124,000 | -19.3% | 9,142,067 | +5.7% | 0.37% | -9.0% |
| Q2 2021 | $27,418,000 | +27.8% | 8,649,300 | +35.9% | 0.41% | +29.3% |
| Q1 2021 | $21,452,000 | +118.0% | 6,365,500 | +131.6% | 0.32% | +124.8% |
| Q4 2020 | $9,841,000 | – | 2,748,999 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rubric Capital Management LP | 10,366,120 | $8,926,000 | 0.45% |
| Clearline Capital LP | 3,957,135 | $3,407,000 | 0.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,364,438 | $6,342,000 | 0.26% |
| DAFNA Capital Management LLC | 1,096,513 | $944,000 | 0.25% |
| Privium Fund Management (UK) Ltd | 177,200 | $153,000 | 0.20% |
| Orbimed Advisors | 10,605,522 | $9,132,000 | 0.17% |
| Octagon Capital Advisors LP | 1,000,000 | $861,000 | 0.15% |
| Rock Springs Capital Management LP | 6,244,897 | $5,377,000 | 0.14% |
| Boxer Capital, LLC | 2,250,000 | $1,937,000 | 0.11% |
| Monaco Asset Management SAM | 186,656 | $161,000 | 0.06% |